T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Sequencing Systemic Therapies in Advanced RCC: Is There a Best Strategy?
Thomas Powles,Shanthini M. Crusz +1 more
TL;DR: There is a strong rationale for sequencing targeted therapy in metastatic clear cell renal cancer, but the timing of the switch and the best agent to switch to remains unclear.
Journal ArticleDOI
Immunotherapy for Renal Cancer: Sequencing and Combinations
TL;DR: Therapy for RCC should be tailored based on both patient and tumor characteristics, and the role of predictive biomarkers to select appropriate therapy requires a greater focus, given the multitude of possible therapies.
Journal ArticleDOI
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
Srikala S. Sridhar,Thomas Powles,Shilpa Gupta,Miguel Angel Climent,Jeanny B. Aragon-Ching,Cora N. Sternberg,P. Cislo,Nuno Costa,Alessandra di Pietro,Joaquim Bellmunt,Petros Grivas +10 more
TL;DR: The results of the phase 3 JAVELIN Bladder 100 trial (NCT02603432) showed significantly longer OS and progression-free survival (PFS) from start of maintenance (randomization) with avelumab maintenance + best supportive care (BSC) vs BSC alone (median OS, 23.8 vs 15.0 months) as mentioned in this paper .
Journal ArticleDOI
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
Robert Huddart,Arlene O. Siefker-Radtke,Arjun Vasant Balar,Mehmet Asim Bilen,Thomas Powles,Aristotelis Bamias,Daniel Castellano,Maged F. Khalil,Michiel S. van der Heijden,Vadim S. Koshkin,David Pook,Mustafa Ozguroglu,Linda Santiago,Bob Zhong,David Chien,Wei Lin,Mary Tagliaferri,Yohann Loriot +17 more
TL;DR: The Phase II PIVOT-10 study (NCT03785925), evaluates efficacy and safety of first-line BEMPEG plus nivolumab in cisplatin-ineligible patients with locally advanced or mUC.
Journal ArticleDOI
Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).
Manuel Caitano Maia,Neeraj Agarwal,Bradley Alexander McGregor,Ulka N. Vaishampayan,Toni K. Choueiri,Marjorie C. Green,Colin Hessel,Christian Scheffold,Gisela Schwab,Thomas Powles,Sumanta K. Pal +10 more
TL;DR: The study design of an ongoing phase 1b study combining CABO with Atezolizumab, an anti-PD-L1 mAb is presented, which may facilitate an immune-permissive tumor environment and may enhance response to immune checkpoint inhibitors.